Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (NCT06467357)
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Who can join: Review the eligibility criteria below.
Location: Research Site — Scottsdale, Arizona
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (269 Sites)
Showing the first 25 of 269 sites.
- Research Site — Scottsdale, Arizona
- Research Site — Tucson, Arizona
- Research Site — Tucson, Arizona
- Research Site — Fullerton, California
- Research Site — La Jolla, California
- Research Site — Los Alamitos, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — San Francisco, California
- Research Site — Walnut Creek, California
- Research Site — Washington D.C., District of Columbia
- Research Site — Fort Myers, Florida
- Research Site — Jacksonville, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Tampa, Florida
- Research Site — West Palm Beach, Florida
- Research Site — Atlanta, Georgia
- Research Site — Coeur d'Alene, Idaho
- Research Site — Chicago, Illinois
- Research Site — Niles, Illinois
- Research Site — Towson, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Worcester, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — Grand Rapids, Michigan
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Biliary Tract Cancer
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Birmingham, Alabama
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Tucson, Arizona
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
- XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Phoenix, Arizona
Explore by condition: All Biliary Tract Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.